Submitted by Anonymous (not verified) on 25 April 2025 - 13:36
Opinion/decision on a Paediatric investigation plan (PIP): Enspryng, satralizumab, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Nervous system disorders;Neurology, PIP number: P/0069/2024
Source: